Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery

International Journal of Pharmaceutics

Volumn 453, Issue 1, 2013, Pages 157-166

  Brough, Chris ^a,b   Williams III, R O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b DisperSol Technologies LLC   (United States)

Author keywords

Amorphous solid dispersions; Nano crystal; Nanoparticles; Poorly water soluble drugs

Indexed keywords

APREPITANT; ETRAVIRINE; EVEROLIMUS; FENOFIBRATE; ITRACONAZOLE; IVACAFTOR; LOPINAVIR PLUS RITONAVIR; MEGESTROL ACETATE; NABILONE; NANOCRYSTAL; PALIPERIDONE; RAPAMYCIN; RITONAVIR; TACROLIMUS; TELAPREVIR; VEMURAFENIB; WATER;

BIOPHARMACEUTICAL CLASSIFICATION SYSTEM; CRYSTALLIZATION; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; HUMAN; INTESTINE ABSORPTION; PARTICLE SIZE; PHARMACOLOGICAL PARAMETERS; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; SOLVATION; THERMODYNAMICS;

EID: 84884167198     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.05.061     Document Type: Review

References (92)

1. Arunkumar, N., Deecaraman, M., Rani, C., 2009. Nanosuspension technology and its applications in drug delivery. Asian J. Pharm. 3, 168.
2. Bauer, J., Spanton, S., Henry, R., Quick, J., Dziki, W., Porter, W., Morris, J., 2001. Ritonavir: an extraordinary example of conformational polymorphism. Pharm. Res. 18, 859-866. (Pubitemid 32783524)
3. Brouwers, J., Brewster, M.E., Augustijns, P., 2009. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J. Pharm. Sci. 98, 2549-2572.
4. Brunner, E., 1904. Reaktionsgeschwindigkeit in heterogenen Systemen. Z. Phys. Chem. 47, 56-102.
5. Chemburkar, S.R., Bauer, J., Deming, K., Spiwek, H., Patel, K., Morris, J., Henry, R., Spanton, S., Dziki, W., Porter, W., Quick, J., Bauer, P., Donaubauer, J., Narayanan, B.A., Soldani, M., Riley, D., McFarland, K., 2000. Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. Org. Process Res. Dev. 4, 413-417.
6. Choi, J.-Y., Yoo, J.Y., Kwak, H.-S., Uk Nam, B., Lee, J., 2005. Role of polymeric stabilizers for drug nanocrystal dispersions. Curr. Appl. Phys. 5, 472-474. (Pubitemid 40714976)
7. Chokshi, R.J., Shah, N.H., Sandhu, H.K., Malick, A.W., Zia, H., 2008. Stabilization of low glass transition temperature indomethacin formulations: impact of polymertype and its concentration. J. Pharm. Sci. 97, 2286-2298.
8. Cooper, E.R., 2010. Nanoparticles: a personal experience for formulating poorly water soluble drugs. J. Control. Release 141, 300-302.
9. Crowley, M.M., Zhang, F., Repka, M.A., Thumma, S., Upadhye, S.B., Kumar Battu, S., McGinity, J.W., Martin, C., 2007. Pharmaceutical applications of hot-melt extrusion: part I. Drug Dev. Ind. Pharm. 33, 909-926. (Pubitemid 47463803)
10. Curatolo, W., Nightingale, J.A., Herbig, S.M., 2009. Utility of hydroxypropylmethylcellulose acetate succinate (HPMCAS) for initiation and maintenance of drug supersaturation in the GI milieu. Pharm. Res. 26, 1419-1431.
11. Dahan, A., Miller, J.M., Amidon, G.L., 2009. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J. 11, 740-746.
12. de Waard, H., Hinrichs, W.L.J., Frijlink, H.W., 2008. A novel bottom-up process to produce drug nanocrystals: controlled crystallization during freeze-drying. J. Control. Release 128, 179-183.
13. DiNunzio, J.C., Miller, D.A., Yang, W., McGinity, J.W., Williams III, R.O., 2008. Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole. Mol. Pharm. 5, 968-980.
14. Dressman, J.B., Vertzoni, M., Goumas, K., Reppas, C., 2007. Estimating drug solubility in the gastrointestinal tract. Adv. Drug Deliv. Rev. 59, 591-602. (Pubitemid 47287780)
15. Fakes, M.G., Vakkalagadda, B.J., Qian, F., Desikan, S., Gandhi, R.B., Lai, C., Hsieh, A., Franchini, M.K., Toale, H., Brown, J., 2009. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. Int. J. Pharm. 370, 167-174.
16. Fenske, D.B., Chonn, A., Cullis, P.R., 2008. Liposomal nanomedicines: an emerging field. Toxicol. Pathol. 36, 21-29.
17. Fini, A., Rodriguez, L., Cavallari, C., Albertini, B., Passerini, N., 2002. Ultrasound-compacted and spray-congealed indomethacin/polyethyleneglycol systems. Int. J. Pharm. 247, 11-22. (Pubitemid 35341135)
18. Galli, C., 2006. Experimental determination of the diffusion boundary layer width of micron and submicron particles. Int. J. Pharm. 313, 114-122.
19. Gullapalli, R.P., 2010. Soft gelatin capsules (softgels). J. Pharm. Sci. 99, 4107-4148.
20. Guzmán, H.R., Tawa, M., Zhang, Z., Ratanabanangkoon, P., Shaw, P., Gardner, C.R., Chen, H., Moreau, J.P., Almarsson, Ö., Remenar, J.F., 2007. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J. Pharm. Sci. 96, 2686-2702. (Pubitemid 47597818)
21. Hancock, B.C., Parks, M., 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 17, 397-404. (Pubitemid 30395293)
22. Hancock, B.C., Shamblin, S.L., Zografi, G., 1995. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm. Res. 12, 799-806.
23. Harmon, A., 2010a. After Long Fight. Drug Gives Sudden Reprieve, The New York Times.
24. Harmon, A., 2010b. A Roller Coaster Chase for a Cure. The New York Times, New York City.
25. Hoy, S.M., Scott, L.J., Keating, G.M., 2010. Intramuscular paliperidone palmitate. CNS drugs 24, 227-244.
26. Huang, J., Wigent, R.J., Schwartz, J.B., 2008. Drug-polymer interaction and its significance on the physical stability of nifedipine amorphous dispersion in microparticles of an ammonio methacrylate copolymer and ethylcellulose binary blend. J. Pharm. Sci. 97, 251-262.
27. Huang, L.-F., Tong, W.-Q., 2004. Impact of solid state properties on developability assessment of drug candidates. Adv. Drug Deliv. Rev. 56, 321-334. (Pubitemid 38201428)
28. Janssens, S., Nagels, S., Armas H.N. d. D'Autry, W., Van Schepdael, A., Van den Mooter, G., 2008. Formulation and characterization of ternary solid dispersions made up of Itraconazole and two excipients, TPGS 1000 and PVPVA 64, that were selected based on a supersaturation screening study. Eur. J. Pharm. Biopharm. 69, 158-166.
29. Janssens, S., Van den Mooter, G., 2010. Review: physical chemistry of solid dispersions. J. Pharm. Pharmacol. 61, 1571-1586.
30. Junghanns, J.U.A.H., Müller, R.H., 2008. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomed. 3, 295.
31. Karavas, E., Georgarakis, E., Sigalas, M.P., Avgoustakis, K., Bikiaris, D., 2007. Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. Eur. J. Pharm. Biopharm. 66, 334-347. (Pubitemid 46778978)
32. Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., Onoue, S., 2011. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. Int. J. Pharm. 420, 1-10.
33. Keserü, G.M., Makara, G.M., 2009. The influence of lead discovery strategies on the properties of drug candidates. Nat. Rev. Drug Dis. 8, 203-212.
34. Kesisoglou, F., Panmai, S., Wu, Y., 2007. Nanosizing - Oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 59, 631-644. (Pubitemid 47285408)
35. Kipp, J.E., 2004. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int. J. Pharm. 284, 109-122. (Pubitemid 39349144)
36. Klein, C.E., Chiu, Y.L., Awni, W., Zhu, T., Heuser, R.S., Doan, T., Breitenbach, J., Morris, J.B., Brun, S.C., Hanna, G.J., 2007. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J. Acquir. Immune Defic. Syndr. 44, 401-410. (Pubitemid 46555374)
37. Konno, H., Taylor, L.S., 2006. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J. Pharm. Sci. 95, 2692-2705. (Pubitemid 46093176)
38. Ku, M.S., Dulin, W., 2012. A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept. Pharm. Dev. Technol. 17, 285-302.
39. Kwong, E., Higgins, J., Templeton, A.C., 2011. Strategies for bringing drug delivery tools into discovery. Int. J. Pharm. 412, 1-7.
40. Lee, J., Choi, J.Y., Park, C.H., 2008. Characteristics of polymers enabling nanocomminution of water-insoluble drugs. Int. J. Pharm. 355, 328-336.
41. Lee, S., Nam, K., Kim, M., Jun, S., Park, J.-S., Woo, J., Hwang, S.-J., 2005. Preparation and characterization of solid dispersions of itraconazole by using aerosol solvent extraction system for improvement in drug solubility and bioavailability. Arch. Pharm. Res. 28, 866-874. (Pubitemid 43080167)
42. Letchford, K., Burt, H., 2007. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur. J. Pharm. Biopharm. 65, 259-269. (Pubitemid 46321600)
43. Lindfors, L., Forssén, S., Westergren, J., Olsson, U., 2008. Nucleation and crystal growth in supersaturated solutions of a model drug. J. Colloid Interface Sci. 325, 404-413.
44. Lipinski, C.A., 2000. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235-249. (Pubitemid 32239479)
45. Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., 2012. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 64, 4-17.
46. Merisko-Liversidge, E., Liversidge, G.G., 2011. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv. Drug Deliv. Rev. 63, 427-440.
47. Merisko-Liversidge, E., Liversidge, G.G., Cooper, E.R., 2003. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18, 113-120. (Pubitemid 36184748)
48. Merisko-Liversidge, E.M., Liversidge, G.G., 2008. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol. 36, 43-48.
49. Miller, D.A., DiNunzio, J.C., Yang, W., McGinity, J.W., Williams III, R.O., 2008a. Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following acidic-to-neutral pH transition. Drug Dev. Ind. Pharm. 34, 890-902.
50. Miller, D.A., DiNunzio, J.C., Yang, W., McGinity, J.W., Williams, R.O., 2008b. Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption. Pharm. Res. 25, 1450-1459.
51. Miller, D.A., et al., 2012. KinetiSol: a new processing paradigm for amorphous solid dispersion systems. Drug Develop. Deliv., 12.
52. Möschwitzer, J., 2010. Particle size reduction technologies in the pharmaceutical development process. Am. Pharm. Rev. 2010, 54-59.
53. Möschwitzer, J., Müller, R.H., Hunter, R., Preedy, V., 2011. Nanocrystal formulations for improved delivery of poorly soluble drugs. Nanomed. Health Dis. 79, 79-99, Chapter 5.
54. Möschwitzer, J.P., 2012. Drug nanocrystals in the commercial pharmaceutical development process. Int. J. Pharm..
55. Muchow, M., Maincent, P., Müller, R.H., 2008. Lipid nanoparticles with a solid matrix (SLN®, NLC®, LDC®) for oral drug delivery. Drug Dev. Ind. Pharm. 34, 1394-1405.
56. Nernst, W., 1904. Theorie der Reaktionsgeschwindigkeit in heterogenen Systemen. Z. phys. Chem. 47, 52-55.
57. Neslihan Gursoy, R., Benita, S., 2004. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother. 58, 173-182. (Pubitemid 38479922)
58. Qian, F., Huang, J., Hussain, M.A., 2010. Drug-polymer solubility and miscibility: stability consideration and practical challenges in amorphous solid dispersion development. J. Pharm. Sci. 99, 2941-2947.
59. Raghavan, S.L., Schuessel, K., Davis, A., Hadgraft, J., 2003. Formation and stabilisation of triclosan colloidal suspensions using supersaturated systems. Int. J. Pharm. 261, 153-158. (Pubitemid 36962753)
60. Raghavan, S.L., Trividic, A., Davis, A.F., Hadgraft, J., 2001. Crystallization of hydrocortisone acetate: influence of polymers. Int. J. Pharm. 212, 213-221. (Pubitemid 32119447)
61. Schultheiss, N., Newman, A., 2009. Pharmaceutical cocrystals and their physicochemical properties. Cryst. Growth Des. 9, 2950-2967.
62. Serajuddin, A.T.M., 2007. Salt formation to improve drug solubility. Adv. Drug Deliv. Rev. 59, 603-616. (Pubitemid 47285406)
63. Serajuddin, A.T.M., Pudipeddi, M., 2008. Salt-selection strategies. In: Handbook of Pharmaceutical Salts Properties, Selection and Use. Weinheim, Wiley-VCH, pp. 135-160.
64. Shah, N., Sandhu, H., Phuapradit, W., Pinal, R., Iyer, R., Albano, A., Chatterji, A., Anand, S., Choi, D.S., Tang, K., 2012. Development of novel microprecipitated bulk powder (MBP) technology for manufacturing stable amorphous formulations of poorly soluble drugs. Int. J. Pharm..
65. Shchekin, A., Rusanov, A., 2008. Generalization of the Gibbs-Kelvin-Köhler and Ostwald-Freundlich equations for a liquid film on a soluble nanoparticle. J. Chem. Phys. 129, 154116.
66. Shegokar, R., Müller, R.H., 2010. Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives. Int. J. Pharm. 399, 129-139.
67. Shen, L.J., 2007. Nanomedicines in renal transplant rejection-focus on sirolimus. Int. J. Nanomed. 2, 25-32.
68. Sherman, E.M., Steinberg, J.G., 2011. Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV. Expert Opin. Pharmacother. 12, 141-148.
69. Sigfridsson, K., Forssén, S., Holländer, P., Skantze, U., de Verdier, J., 2007. A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound. Eur. J. Pharm. Biopharm. 67, 540-547. (Pubitemid 47225040)
70. Singh, A., Worku, Z.A., Van den Mooter, G., 2011. Oral formulation strategies to improve solubility of poorly water-soluble drugs. Expert Opin. Drug Deliv. 8, 1361-1378.
71. Singhal, D., Curatolo, W., 2004. Drug polymorphism and dosage form design: a practical perspective. Adv. Drug Deliv. Rev. 56, 335-347. (Pubitemid 38201429)
72. Six, K., Berghmans, H., Leuner, C., Dressman, J., Van Werde, K., Mullens, J., Benoist, L., Thimon, M., Meublat, L., Verreck, G., 2003. Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion, part II. Pharm. Res. 20, 1047-1054. (Pubitemid 36774276)
73. Stella, V.J., He, Q., 2008. Cyclodextrins. Toxicol. Pathol. 36, 30-42.
74. Stephenson, G.A., Aburub, A., Woods, T.A., 2011. Physical stability of salts of weak bases in the solid-state. J. Pharm. Sci. 100, 1607-1617.
75. Takagi, T., Ramachandran, C., Bermejo, M., Yamashita, S., Lawrence, X.Y., Amidon, G.L., 2006. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol. Pharm. 3, 631-643. (Pubitemid 46087480)
76. Texter, J., 2001. Precipitation and condensation of organic particles. J. Disper. Sci. Technol. 22, 499-527. (Pubitemid 34128768)
77. Thombre, A.G., Herbig, S.M., Alderman, J.A., 2011. Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect. Pharm. Res. 28, 3159-3170.
78. Thombre, A.G., Shah, J.C., Sagawa, K., Caldwell, W.B., 2012. In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations. Int. J. Pharm. 428, 8-17.
79. Van Eerdenbrugh, B., Van den Mooter, G., Augustijns, P., 2008. Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products. Int. J. Pharm. 364, 64-75.
80. Vasanthavada, M., Tong, W.Q., Joshi, Y., Kislalioglu, M.S., 2004. Phase behavior of amorphous molecular dispersions I: determination of the degree and mechanism of solid solubility. Pharm. Res. 21, 1598-1606. (Pubitemid 41184390)
81. Vehring, R., 2008. Pharmaceutical particle engineering via spray drying. Pharm. Res. 25, 999-1022.
82. Verreck, G., Six, K., Van den Mooter, G., Baert, L., Peeters, J., Brewster, M.E., 2003. Characterization of solid dispersions of itraconazole and hydroxypropylmethyl-cellulose prepared by melt extrusion - part I. Int. J. Pharm. 251, 165-174. (Pubitemid 36071471)
83. Vogt, M., Kunath, K., Dressman, J.B., 2008. Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations. Eur. J. Pharm. Biopharm. 68, 283-288.
84. Voorhees, P.W., 1985. The theory of Ostwald ripening. J. Stat. Phys. 38, 231-252.
85. Wang, X., Michoel, A., Van den Mooter, G., 2005. Solid state characteristics of ternary solid dispersions composed of PVP VA64, Myrj 52 and itraconazole. Int. J. Pharm. 303, 54-61. (Pubitemid 41318021)
86. Waterman, K.C., MacDonald, B.C., 2010. Package selection for moisture protection for solid, oral drug products. J. Pharm. Sci. 99, 4437-4452.
87. Wu, C.-Y., Benet, L.Z., 2005. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22, 11-23. (Pubitemid 40558141)
88. Wu, C., McGinity, J.W., 2001. Influence of ibuprofen as a solid-state plasticizer in Eudragit® RS 30 D on the physicochemical properties of coated beads. AAPS PharmSciTech 2, 35-43.
89. Wu, Y., Loper, A., Landis, E., Hettrick, L., Novak, L., Lynn, K., Chen, C., Thompson, K., Higgins, R., Batra, U., Shelukar, S., Kwei, G., Storey, D., 2004. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 285, 135-146. (Pubitemid 39361543)
90. Yu, L.X., Amidon, G.L., Polli, J.E., Zhao, H., Mehta, M.U., Conner, D.P., Shah, V.P., Lesko, L.J., Chen, M.-L., Lee, V.H., 2002. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. 19, 921-925. (Pubitemid 34804232)
91. Zhao, Y.H., Abraham, M.H., Le, J., Hersey, A., Luscombe, C.N., Beck, G., Sherborne, B., Cooper, I., 2002. Rate-limited steps of human oral absorption and QSAR studies. Pharm. Res. 19, 1446-1457. (Pubitemid 35266548)
92. Zheng, W., Jain, A., Papoutsakis, D., Dannenfelser, R.M., Panicucci, R., Garad, S., 2012. Selection of oral bioavailability enhancing formulations during drug discovery. Drug Dev. Ind. Pharm. 38, 235-247.